Swedish Medical Center (Ballard Campus)
Seattle, WA
Accepting patients
BMS-986453
A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma
- CAR T Cell
- BCMA
- GPRC5D
- Phase 1
Accepting patients
Etentamig with Iberdomide
Phase 1/2 Study of Etentamig in Combination With a CELMoD Agent for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma
- Bispecific Antibody
- CELMoD
- BCMA
- Phase 1
Accepting patients
Triplet Induction + 1 or 2-Drug Maintenance
A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance
- Monoclonal Antibody
- CD38
- Randomization
- Maintenance
- Phase 3
Not currently accepting
EQUATE
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- Monoclonal Antibody
- CD38
- Phase 3
Accepting patients
LINKER-MM1
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma (LINKER-MM1)
- Bispecific Antibody
- BCMA
- Phase 1/2
- Has results
Not currently accepting
Early Detection Blood Tests
Blinded Reference Set for Multicancer Early Detection Blood Tests
- Observational Trial